Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma
NB is identified as a highly NAMPT inhibitor-sensitive pediatric solid tumor and NAMPT-dependent NAD + biosynthesis as a targetable metabolic vulnerability in this disease is established.